Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Update

Bionano Genomics, Inc. (NASDAQ:BNGO) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 341,500 shares, a drop of 98.1% from the December 31st total of 17,650,000 shares. Based on an average daily volume of 143,900 shares, the short-interest ratio is presently 2.4 days. Currently, 14.7% of the company’s shares are short sold.

Bionano Genomics Trading Up 11.9 %

BNGO stock traded up $0.61 during midday trading on Thursday, hitting $5.75. The stock had a trading volume of 386,173 shares, compared to its average volume of 365,262. The company has a current ratio of 1.43, a quick ratio of 0.99 and a debt-to-equity ratio of 0.07. The business has a fifty day moving average price of $12.97 and a two-hundred day moving average price of $21.32. Bionano Genomics has a 1-year low of $4.95 and a 1-year high of $81.00. The firm has a market cap of $672.29 million, a P/E ratio of -2.48 and a beta of 2.22.

Institutional Investors Weigh In On Bionano Genomics

Several large investors have recently added to or reduced their stakes in BNGO. Geode Capital Management LLC boosted its holdings in shares of Bionano Genomics by 47.3% during the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after buying an additional 283,639 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Bionano Genomics during the 3rd quarter valued at $46,000. Finally, Carret Asset Management LLC boosted its stake in Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after acquiring an additional 40,055 shares in the last quarter. Institutional investors and hedge funds own 11.35% of the company’s stock.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.